Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Edwards Lifesciences (EW) PT Raised to $136 at Jefferies Following Investor Day
December 8, 2017 6:50 AM ESTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $136.00 (from $132.00) while maintaining a Buy rating.
Analyst Raj Denhoy highlighted three conclusions from EWs annual investor briefing:
1. With efforts to tap less sick, undiagnosed, and untreated populations along with continued... More
Edwards Lifesciences (EW) PT Raised to $135 at Cowen
December 8, 2017 6:40 AM ESTCowen raised its price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $130.00) while maintaining a Outperform rating.
Analyst Joshua Jennings said EW's 2018 targets are likely conservative and were well received. Jennings said the update to the WW TAVR franchise leaves room for 2018 upside and... More
